Background*

Mr. Mark W. Leuchtenberger has been the Chief Executive Officer and President of Acusphere, Inc., since September 2013. Mr. Leuchtenberger served as the President of Melinta Therapeutics, Inc. since March 23, 2010 and served as its Chief Executive Officer since March 23, 2010. He is a co-founder of Albor Biologics, Inc. and Alvos Therapeutics, Inc. Before joining Acusphere in 2013, Mr. Leuchtenberger served as President and Chief Executive Officer at Rib-X Pharmaceuticals ... from 2010 to 2013. Mr. Leuchtenberger served as the Chief Executive Officer and President of Targanta Therapeutics Corp. (also called as Targanta Therapeutics Inc.,) from September 18, 2006 to February 25, 2009. He served as the President and Chief Executive Officer of Therion Biologics Corporation from 2002 to 2006. Prior to Therion in 2002, Mr. Leuchtenberger served as Vice President of International of Biogen Idec Ma Inc. from 1999 to 2002, which he joined in 1990 as Product Manager and served as Program Executive of Biogen's commercial products Amevive(R) and Avonex(R). He spent 11 years at Biogen, where Mr. Leuchtenberger was responsible for managing the late-stage development, registration, marketing and North American launch of Avonex(R). In his tenure at Biogen, he held several senior positions, including Vice President of Sales, Marketing and Business Development where he oversaw Biogen's global market, licensing and strategic partnership activities. He served as a Senior Consultant of Bain & Co. specializing in healthcare. He has experience in commercial operations, business development and preparing biopharmaceutical companies for product approval and commercialization. He has been Chairman of the Board of Xenetic Biosciences, Inc., since May 2014. He serves as the Chairman of the MassBio Board of Directors. Mr. Leuchtenberger is a Director, Chairman of Compensation Committee and Member of Nominating & Governance Committee at EPIX Pharmaceuticals, Inc. since September 20, 2004, Acusphere, Inc., since September 2013. He serves as a Director of Mercator Therapeutics, Inc., NeuroHealing Pharmaceuticals, Inc. and Alvos Therapeutics, Inc. He served as an Executive Director of Targanta Therapeutics Corp. from September 18, 2006 to February 2009. He serves as a Director of Massachusetts Biotechnology Council, Beth Israel Deaconess Medical Center and Wake Forest University. He served as a member of the Board of Directors at Rib-X Pharmaceuticals from March 23, 2010 to 2013. He served as a Director of Therion Biologics Corporation. Mr. Leuchtenberger holds an M.B.A. from the Yale School of Management and a BA in English from Wake Forest University.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.